Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
NEOsphere Biotechnologies has developed a proprietary high-throughput mass spectrometry-based proteomics platform that enables unbiased screening of small molecule degraders—including molecular glues—across the entire human proteome. The company systematically identifies and validates novel degrader targets at unprecedented depth and scale, supporting pharmaceutical partners in building robust pipelines of first-in-class therapeutics. No direct clinical results reported as the company operates primarily as a discovery engine/platform partner.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on NEOsphere Biotechnologies.